Supported by an educational grant from Axsome Therapeutics, Inc.

Homepage

Featured

Education

Breaking the Monoamine Barrier - The Limits of Monoamines: Why Conventional Antidepressants Fall Short (Module 1)

Videos

MOA Animation: Modulating Glutamate, Inflammation, and Neuroplasticity in Major Depressive Disorder

Faculty

Craig Chepke, MD, DFAPA

Medical Director,
Excel Psychiatric Associates

Rakesh Jain, MD, MPH

Clinical Professor,
Texas Tech - Permian Basin

Desiree Matthews, PMHNP-BC

CEO,
Different MHP, PC

Kristian Dambrino, MSN, APRN, PMHNP-BC

Founder, Psychiatric Nurse Practitioner,
Dambrino Consulting & Wellness LLC

Lara Shirikjian, DO

Principal Investigator,
Medical Director,
Cenexel CNS

Brooke Kempf, PMHNP-BC

Adjunct Faculty,
Indiana University Indianapolis

Saundra Jain, MA, PsyD, LPC

Adjunct Clinical Affiliate,
University of Texas at Austin School of Nursing,
Private Practice, Austin, Texas

Microlearning

Education

Breaking the Monoamine Barrier - The Limits of Monoamines: Why Conventional Antidepressants Fall Short (Module 1)

This first module in the series of Breaking the Monoamine Barrier will focus on describing the limitations of conventional monoaminergic antidepressants that are associated with subop

Education

Breaking the Monoamine Barrier - Beyond Serotonin: The Role of the Glutamatergic System in MDD (Module 2)

In Module 2 of Breaking the Monoamine Barrier, Dr.

Education

Breaking the Monoamine Barrier - Personalizing Treatment: Strategies for Incorporating Glutamatergic Therapy (Module 4)

Breaking the Monoamine Barrier - Glutamatergic Antidepressants in Practice: When and How to Use Them (Module 3)

Videos

Surmounting Challenges in the Treatment of MDD: A Light at the End of the Tunnel

Evolving Perspectives on Depression: Chronic vs. Episodic Treatment in MDD and the Role of the GABA System

Neuroplasticity and Its Role in MDD: New Solutions with Digital Therapeutics

Podcasts

Ketamine for Depression: Why Does It Work So Fast?

Are Glutamatergic Antidepressants Safe for Long-Term Use?

Glutamate Receptors: What Are NMDA, AMPA, and Metabotropic Receptors?

News

Pharmacogenomic Test Improves MDD Response and Remission Outcomes

High Levels of THC in Cannabis Products Associated With Mental Health Risks

FDA Approves TMS Device for Major Depressive Disorder in Adolescents

Posters

Characterization of Care Patterns for Patients Newly Diagnosed With Major Depressive Disorder (MDD) in Primary Care Settings: a Retrospective Observational Cohort Study

Association between Anhedonia Severity and Clinical and Humanistic Outcomes Among US Adults with Major Depressive Disorder

Effectiveness of Vortioxetine in Elderly Patients With Major Depressive Disorder in Real-World Clinical Practice: Results From the RELIEVE Study